AP
QHC

Arlington Partners’s Quorum Health Corporation QHC Stock Holding History

Arlington Partners’s Portfolio QHC Stock Details QHC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-301
Closed – – 226
2019
Q2 		$0 Buy
+301
New +$494 ﹤0.01% 265

Other funds holding QHC

KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
YCMGA
York Capital Management Global Advisors New York $87.8M AUM 45.55% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
OHA
Oak Hill Advisors New York $878M AUM 106.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return
CCM
Contrarian Capital Management Greenwich, Connecticut $357M AUM 18.27% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Arlington Partners's QHC Position: Q3 2019 in Review

Arlington Partners sold out of Quorum Health Corporation (QHC) in Q3 2019, closing a stake of 301 shares.

Arlington Partners first reported a position in QHC in Q2 2019 and held it in 1 quarter. The position peaked at $0 in Q2 2019. 70 funds tracked by Wall St. Rank hold QHC as of Q3 2019.

  • Arlington Partners reported no remaining Quorum Health Corporation position as of Q3 2019 after selling out during the quarter.
  • Arlington Partners sold 301 Quorum Health Corporation shares in Q3 2019.
  • Arlington Partners first reported a position in Quorum Health Corporation in Q2 2019 and held it in 1 quarter.
  • Arlington Partners's Quorum Health Corporation position peaked at $0 in Q2 2019.
  • 70 funds tracked by Wall St. Rank held Quorum Health Corporation as of Q3 2019.

Based on Arlington Partners's 13F filing for Q3 2019, filed 18 Oct 2019.